This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 1986 Oct 25;2(8513):985-6.

doi: 10.1016/s0140-6736(86)90642-2.

When should levodopa be started?

N Quinn, P Critchley, D Parkes, C D Marsden

PMID: 2877169
DOI: 10.1016/s0140-6736(86)90642-2

When should levodopa be started?

N Quinn et al. Lancet. 1986.

. 1986 Oct 25;2(8513):985-6.

doi: 10.1016/s0140-6736(86)90642-2.

Authors

N Quinn, P Critchley, D Parkes, C D Marsden

PMID: 2877169
DOI: 10.1016/s0140-6736(86)90642-2

No abstract available

PubMed Disclaimer

Similar articles

What to do when Sinemet fails: Part one.
Klawans HL. Klawans HL. Clin Neuropharmacol. 1984;7(2):121-33. Clin Neuropharmacol. 1984. PMID: 6733692 No abstract available.
Sickness due to levodopa-induced neck dyskinesias in Parkinson's disease.
Steiger MJ, Quinn NP, Marsden CD. Steiger MJ, et al. Mov Disord. 1991;6(1):91-2. doi: 10.1002/mds.870060122. Mov Disord. 1991. PMID: 2005934 No abstract available.
Does tolerance develop to levodopa? Comparison of 2- and 21-H levodopa infusions.
Nutt JG, Carter JH, Woodward W, Hammerstad JP, Gancher ST. Nutt JG, et al. Mov Disord. 1993 Apr;8(2):139-43. doi: 10.1002/mds.870080204. Mov Disord. 1993. PMID: 8474479
Optimising levodopa therapy for the management of Parkinson's disease.
Stocchi F. Stocchi F. J Neurol. 2005 Oct;252 Suppl 4:IV43-IV48. doi: 10.1007/s00415-005-4009-4. J Neurol. 2005. PMID: 16222437 Review.
[Therapy for patients with progressive Parkinson's disease].
Murata M. Murata M. Nihon Naika Gakkai Zasshi. 2003 Aug 10;92(8):1432-7. Nihon Naika Gakkai Zasshi. 2003. PMID: 13677891 Review. Japanese. No abstract available.

See all similar articles

Cited by

Cabergoline for levodopa-induced complications in Parkinson's disease.
Clarke CE, Deane KH. Clarke CE, et al. Cochrane Database Syst Rev. 2001;2001(1):CD001518. doi: 10.1002/14651858.CD001518. Cochrane Database Syst Rev. 2001. PMID: 11279720 Free PMC article.
Lisuride for levodopa-induced complications in Parkinson's disease.
Clarke CE, Speller JM. Clarke CE, et al. Cochrane Database Syst Rev. 2000;1999(2):CD001515. doi: 10.1002/14651858.CD001515. Cochrane Database Syst Rev. 2000. PMID: 10796801 Free PMC article.
Amantadine for dyskinesia in Parkinson's disease.
Crosby NJ, Deane KH, Clarke CE. Crosby NJ, et al. Cochrane Database Syst Rev. 2003;2003(2):CD003467. doi: 10.1002/14651858.CD003467. Cochrane Database Syst Rev. 2003. PMID: 12804468 Free PMC article.
Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Clarke CE, Deane KD. Clarke CE, et al. Cochrane Database Syst Rev. 2001;2001(1):CD001519. doi: 10.1002/14651858.CD001519. Cochrane Database Syst Rev. 2001. PMID: 11279721 Free PMC article.
Pramipexole for levodopa-induced complications in Parkinson's disease.
Clarke C E, Speller J M, Clarke J A. Clarke C E, et al. Cochrane Database Syst Rev. 2000;2000(3):CD002261. doi: 10.1002/14651858.CD002261. Cochrane Database Syst Rev. 2000. PMID: 10908540 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science